TL-300 Approved for use in China

The TL-300 has been approved by the State Food and Drug Administration (SFDA), the Chinese healthcare regulator, for release onto the market in the People's Republic of China.

It was developed by Tensys Medical Inc., which produces and commercialises hemodynamic patient monitoring systems.

TL-300 can be used to monitor patients' blood pressure, capturing their beat-to-beat waveform and provides real-time hemodynamic data to clinicians. At present it is the only non-invasive technology that can provide up to date hemodynamic information on the Chinese market.

Initially it will be concentrated into markets for operating rooms and intensive care units.

Vice president of sales and marketing at Tensys Dr Eric Daniels said: "This approval represents a significant achievement in our expansion to the Asian markets and strengthens our leadership position in the field of non-invasive hemodynamic monitoring."

Hemodynamic monitoring can be used to detect issues in patients such as changes in blood pressure due to age and septic shock.